Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis. - Wikidata - wikimedia - TriplyDB

Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis.

Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis.

http://www.wikidata.org/entity/Q37896546

about

Management of glucocorticoid-induced osteoporosis: clinical data in relation to disease demographics, bone mineral density and fracture risk.A review of lifestyle, smoking and other modifiable risk factors for osteoporotic fractures.Patterns of bisphosphonates utilization in patients under age 45 in a large cohort of commercial insurance beneficiaries in the United States Inhaled corticosteroids and bone health Clinical utility of denosumab for treatment of bone loss in men and women Prevention of glucocorticoid induced bone changes with beta-ecdysone.Management of severe osteoporosis.Zoledronic acid-induced hepatotoxicity relieved after subsequent infusions in a Chinese woman with glucocorticoid-induced osteoporosis Influence of bisphosphonate therapy on bone geometry, volumetric bone density and bone strength of femoral shaft in postmenopausal women with rheumatoid arthritis Glucocorticoid-induced osteoporosis and osteonecrosis.Clinical role of bisphosphonate therapy.Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis.Cortical remodeling during menopause, rheumatoid arthritis, glucocorticoid and bisphosphonate therapy.Systemic glucocorticoids: important issues and practical guidelines for the dermatologist.New anabolic therapies for osteoporosis.Clinically applicable antianginal agents suppress osteoblastic transformation of myogenic cells and heterotopic ossifications in mice.Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines.Romosozumab: from basic to clinical aspects.The diagnosis and management of primary autoimmune haemolytic anaemia.Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?Glucocorticoid therapy as a significant risk factor for osteoporosis and fractures in an Italian postmenopausal population.

P2860

Q30946308-EAAD204A-5541-4B00-B427-759BBE07E6BC Q34171853-E918A381-7BD4-48BB-B1DB-BDE04414FAC4 Q35001586-89A718DA-0EFF-4126-BD2C-BBC801964796 Q35056142-A3E73DD4-2086-4E8C-93FD-BE21369328F8 Q35092799-34189A0B-61CE-48F3-9E62-DE2A1B9ABB46 Q35163490-01617569-12F1-41F2-9A91-CE606361349D Q35852252-87E1D29D-EB8B-41FE-BF48-51E21C3365C3 Q35986961-097681CD-E554-4EDE-9674-9A7CFA34DE45 Q36095188-17490C1D-495C-415E-BEF1-A76D5CA7A64C Q36157622-40C3E52E-2442-4612-BF9B-C73360E14906 Q36311593-F5DDBAFB-09F7-4D5C-ACA8-B8F3F3962F4F Q36873339-57E6980E-FD91-4D80-9BFD-E317F9FC42D3 Q36903439-B7452CBD-DB13-4C97-B346-23D74CEDABC8 Q38356324-5535DABE-508E-48C6-A3E6-8D7CCE98DEE4 Q38646406-6CF2A024-5C74-41A5-8997-791BE665A1D6 Q39271486-51D8CBEF-730F-4122-B2D5-8F1BDFFADB9E Q45045554-E269856D-3857-401B-A3D0-3B79DD03EB5E Q45424127-D5BA4951-BCBE-479B-9DEC-2C0FA0CFFEB3 Q48124799-3CB965F8-D468-470F-B4B2-E57A83ACBB0B Q48908924-712074A8-2E95-4B9B-8C05-32CBF9C8982A Q51814416-A900807C-789B-40B4-BE20-11C9390210B5

P2860

Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis.

http://www.wikidata.org/entity/Q37896546

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 30 June 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis.

@en

Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis.

@nl

type

label

Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis.

@en

Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis.

@nl

prefLabel

Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis.

@en

Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis.

@nl

P1433

Q37896546-89A75FC8-04D1-45E1-9308-FB3C923C3164

P1476

Q37896546-BC92BAA5-AFAC-4D56-B125-8CA37E18762F

P2093

Q37896546-1D722C7E-DFD5-40A2-A3FC-FB0D9E9B5AA8

Q37896546-39EF256F-0968-43E7-ABD3-BD972600E8F8

Q37896546-7DF15F4E-A059-49E3-AC4A-657A97DAA484

Q37896546-8E3F8D4E-4516-46C5-91B6-5D8C5D40A4AB

Q37896546-B56965C4-5A89-412A-BA5F-9D868E47A4FF

Q37896546-EB687B4F-59DE-4EE5-8A2D-8DFA9A6D653F

P2860

Q37896546-0B5D8F96-6016-4A99-8004-DA4E8F040141

Q37896546-0E8C25BA-46A6-4E12-B1EC-BA3F56CE8764

Q37896546-301FB97A-D108-49CA-9411-F13AA628D479

Q37896546-4173C0E0-1B52-4F02-ABA9-70E8FD9F7A42

Q37896546-4E3555A2-00CC-4A17-826E-89AEF5598F8D

Q37896546-5645D23F-6175-41E7-AC88-B36ED1FFCACC

Q37896546-569D9DC1-48B7-4322-AF78-D86522B1952A

Q37896546-58860297-4794-4BB2-809A-F6EFF5896027

Q37896546-5EC2C415-299E-4B06-A879-B708F2957AF4

Q37896546-668C6F4F-1DBE-40F0-A06F-A226956FB0B6

P304

Q37896546-88E1B7E8-B242-44C0-BEE8-9B5E1527EC56

P31

Q37896546-A6B379EA-B5A4-47B9-9CA7-14A04B74883C

P356

Q37896546-2B735BCD-660F-4965-A542-59EF160B3A95

P433

Q37896546-B5D66C0C-8D40-4B25-814D-DDF1CBD7B74C

P478

Q37896546-23E9067A-D29C-41C5-AF9F-DFDFC6C6AB22

P577

Q37896546-13C410CD-6A46-41C9-AC43-2363EA82D725

P5875

Q37896546-BB8ABF06-6007-4E96-8D23-1B7F904131E3

P698

Q37896546-231BA3B1-D787-4A01-82E4-7B8846CCA696

P921

Q37896546-E1674FEE-912B-4BD2-99E5-74D9BAB74EF9

P356

P1433

Journal of Bone and Mineral Research

P1476

Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis.

@en

P2093

Carol Zapalowski

http://www.w3.org/2001/XMLSchema#string

H Alexander Wilson

http://www.w3.org/2001/XMLSchema#string

Howard A Fink

http://www.w3.org/2001/XMLSchema#string

Karen E Hansen

http://www.w3.org/2001/XMLSchema#string

Robert A Adler

http://www.w3.org/2001/XMLSchema#string

Salvatore Minisola

http://www.w3.org/2001/XMLSchema#string

P2860

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 G

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.

Use of oral corticosteroids and risk of fractures.

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.

Underuse of coronary revascularization procedures in patients considered appropriate candidates for revascularization.

Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis.

Management of glucocorticoid induced osteoporosis in premenopausal women with autoimmune disease.

Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone

P304

1989-1996

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JBMR.362

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51459471

http://www.w3.org/2001/XMLSchema#string

P698

21721042

http://www.w3.org/2001/XMLSchema#string

P921